Clinical AI Procurement Checklist

A clinical AI procurement checklist is useful because hospitals should not buy clinical AI like ordinary software. The purchase decision affects patient safety, clinician workflow, privacy, governance, and long-term monitoring. A good checklist slows down the flashy part of the sales cycle and forces the organization to answer the practical questions before a contract or pilot begins.

This checklist is designed for hospitals, health systems, and clinical departments evaluating AI tools for diagnosis, decision support, imaging, documentation, treatment planning, or other patient-care workflows. It works best when used alongside How Hospitals Evaluate Clinical AI Vendors, the broader framing in Clinical Artificial Intelligence: Uses, Evidence, Regulation, and Adoption, and domain-specific reviews such as Radiology AI in Practice: Workflow, Validation, and Implementation.

How to Use This Checklist

Use this checklist before vendor selection is finalized, before a pilot begins, and again before a wider rollout. It is not legal advice and it does not replace formal privacy, compliance, or procurement review. What it does is give the team a shared structure for asking better questions early enough to matter.

The best pattern is cross-functional: clinical owner, operational owner, IT, informatics, privacy, security, legal or compliance, procurement, and end users. NIST's AI RMF Playbook is explicit that its guidance is not a rigid ordered checklist. That is useful here too. The point is not bureaucratic box-checking. The point is disciplined review of risk, fit, and accountability in the real hospital environment.

1. Define the Clinical Problem and Ownership

• State the exact clinical or workflow problem the tool is meant to solve.
• Name the primary users and the department or service line that owns the use case.
• Describe what happens today without the tool.
• Define what failure looks like if the tool performs badly or is misunderstood.
• Identify the physician, clinical leader, or operational sponsor who will own the decision after procurement.

If the use case is vague, stop here. A hospital that cannot describe the problem clearly is not ready to compare vendors well. This step connects directly to Implementation.

2. Review Evidence and Validation

• Request published validation studies, not only slide decks or internal benchmarks.
• Check whether the evidence is prospective, retrospective, or reader-study based.
• Ask whether external validation was performed.
• Check whether the study population and care setting resemble your own.
• Ask whether the primary outcome is clinically meaningful or only technically impressive.
• Request subgroup information, bias analysis, and known performance limitations.

AHRQ-linked reviews of AI clinical decision support show real promise, but not every tool is backed by equally strong evidence. Treat evidence review as a core procurement step, not an academic extra. Related coverage: Clinical Studies.

3. Confirm Regulatory Status and Intended Use

• Ask whether the product is FDA-cleared, approved, authorized, not regulated as a device, or subject to another pathway.
• Request the exact intended use statement and any labeled limitations.
• Confirm whether the output is meant to inform, triage, prioritize, quantify, document, or directly influence treatment decisions.
• Ask how updates are versioned and disclosed over time.
• For regulated products, ask how change control and postmarket monitoring are handled.

The FDA's public AI-enabled device list is useful for transparency, but the agency also states that it is not comprehensive. Regulatory status matters, but it does not replace local review of workflow fit and evidence. Related coverage: FDA and Regulation.

4. Test Workflow Fit

• Map where the output appears in the current workflow.
• Identify who sees it first and who is expected to act on it.
• Check whether the product adds clicks, latency, or new manual review steps.
• Ask how overrides, disagreements, and false positives are handled.
• Determine whether the tool creates alert fatigue or documentation burden elsewhere.
• Have real end users review the workflow, not only leadership.

This is one of the highest-value parts of procurement. A strong model can still fail if it lands badly in the workflow. For imaging teams, this connects to Workflow. For documentation-heavy use cases, it connects to AI Physician Workflow.

5. Review Privacy, Security, and Data Governance

• Document what protected health information enters the system.
• Ask where the data is stored, processed, and retained.
• Request the vendor's position on customer-data use for model improvement or training.
• Review access controls, logging, incident response, and subprocessor exposure.
• Determine whether a BAA is required and whether the contract language matches the real data flow.
• Confirm whether de-identification claims are operationally credible for the specific workflow.

Joint Commission's June 1, 2026 RUAIH launch explicitly framed responsible AI as a governance, privacy, trust, and patient-safety issue. That is why privacy review belongs in the main procurement sequence, not at the end. Related coverage: Privacy and HIPAA.

6. Check Technical Integration and Operational Readiness

• List every required integration: EHR, PACS, RIS, dictation, SSO, identity, messaging, or data feeds.
• Ask what implementation work the hospital owns versus what the vendor owns.
• Confirm latency, uptime expectations, support hours, and escalation paths.
• Ask what data quality assumptions the model depends on.
• Review sandbox or test-environment requirements before production use.
• Document any dependencies on local hardware, cloud services, or third-party platforms.

A tool that is clinically promising but operationally brittle can still be the wrong purchase. This step is especially important for enterprise imaging, inpatient workflows, and high-volume documentation systems.

7. Review Governance and Monitoring Plan

• Identify the governance group or committee that will oversee the tool.
• Decide what local validation is required before go-live.
• Define post-deployment metrics such as override rates, concordance, drift, safety events, or workflow impact.
• Set review cadence for version changes, incidents, and performance trends.
• Document who can pause or retire the tool if problems emerge.
• Confirm training and education requirements for users and supervisors.

CHAI's governance playbooks and Joint Commission's responsible AI guidance both push hospitals toward structured internal governance rather than one-time product review. Procurement should end with a monitoring plan, not with a signature.

8. Review Commercial and Contract Terms

• Request a clear breakdown of pricing, implementation fees, support costs, and renewal terms.
• Ask what happens if the vendor sunsets the product or changes its architecture.
• Review contract language around updates, downtime, incident reporting, and audit access.
• Check data export rights and transition support if the hospital exits the relationship.
• Ask whether additional modules, seats, sites, or use cases change pricing materially.
• Document hidden costs tied to internal governance, workflow redesign, or manual review.

Total cost of ownership matters more than sticker price. This step connects directly to ROI and Adoption.

9. Define Pilot Scope and Success Criteria

• Write down what the pilot is meant to prove.
• Set concrete success metrics before go-live.
• Define a stop rule for safety, usability, or performance failure.
• Choose the review period and sample size deliberately.
• Make sure the pilot includes the real users and conditions that matter most.
• Separate vendor success metrics from hospital decision metrics.

A pilot without predefined decision criteria is just a prolonged demo. This step pairs closely with How Hospitals Evaluate Clinical AI Vendors.

10. Make a Go, Pilot, or No-Go Decision

• Go when the use case is clear, evidence is credible, workflow fit is strong, privacy and governance concerns are addressed, and the monitoring plan is ready.
• Pilot when the opportunity is real but local validation, workflow testing, or integration proof is still needed.
• No-Go when the evidence is weak, the workflow fit is poor, the vendor is not transparent, privacy or contracting concerns remain unresolved, or internal ownership is unclear.

This is the part many teams skip. A checklist is useful only if it leads to a decision standard that the organization is willing to honor.

Common Reasons to Slow Down Procurement

• The clinical problem is not clearly defined.
• The vendor cannot explain intended use or limitations in practical terms.
• Evidence is mostly internal, retrospective, or hard to match to your setting.
• Privacy and data-use answers are vague.
• Workflow review has not included real users.
• No internal owner has accepted accountability after launch.
• The pilot has no clear success metrics or stop rule.

Related Clinical AI Topics

• Implementation
• Medical AI Vendors
• Privacy and HIPAA
• Clinical Studies
• FDA and Regulation
• How Hospitals Evaluate Clinical AI Vendors
• Clinical Artificial Intelligence: Uses, Evidence, Regulation, and Adoption
• Radiology AI in Practice: Workflow, Validation, and Implementation

Reviewed: July 22, 2026. Next review: October 22, 2026.